PT-141 daily dosage does not exist as a label instruction: bremelanotide is taken as needed, once per 24 hours at most. See the real mg and mL numbers.
There is no approved PT-141 daily dosage. Bremelanotide — sold as Vyleesi — is an as-needed medication, not a daily peptide: the label calls for a single 1.75 mg subcutaneous injection at least 45 minutes before sexual activity, with a maximum of one dose in any 24-hour period and no more than eight doses per month.
If you came here looking for a once-a-day schedule, the short answer is that neither the manufacturer nor the FDA ever studied one. The sections below explain where the 24-hour limit comes from and how the numbers translate into milligrams, milliliters, and syringe units.
Why PT-141 Is Not Dosed Daily
PT-141 (bremelanotide) is a melanocortin receptor agonist that acts on pathways involved in sexual desire. Its effects appear quickly and fade within hours, which is why it is timed around activity rather than taken on a fixed daily schedule.
The plasma half-life of bremelanotide is roughly 2.7 hours. A dose taken in the morning is largely cleared by the afternoon, so stacking a second dose the same day does not extend the benefit — it only increases exposure to side effects.
PT-141 is not FDA-approved for daily use in the United States, and no clinical trial has established a safe daily schedule for bremelanotide.
PT-141 Dosage: The Numbers That Matter
The approved regimen is narrow and specific. Every parameter below comes from the product label, not from forum protocols.
| Parameter | Approved guidance |
|---|---|
| Route | Subcutaneous injection into the abdomen or thigh |
| Single dose | 1.75 mg |
| Timing | At least 45 minutes before sexual activity |
| Repeat dosing | No more than one dose in 24 hours |
| Monthly ceiling | No more than 8 doses per month |
| Approved population | Premenopausal women with hypoactive sexual desire disorder (HSDD) |
Notice the pattern: the schedule is built around need, not around the calendar. Even a person using PT-141 regularly tops out at roughly two doses per week under the monthly cap.
PT-141 Dosage in mg and mL: The Reconstitution Math
Vials sold for research use typically contain 10 mg of lyophilized powder, and the final concentration depends entirely on how much diluent is added. That single variable is what makes random online dose charts so inconsistent.
| Diluent added to a 10 mg vial | Concentration | Volume for a 1.75 mg dose | U-100 syringe units |
|---|---|---|---|
| 1 mL | 10 mg/mL | 0.175 mL | 17.5 units |
| 2 mL | 5 mg/mL | 0.35 mL | 35 units |
| 3 mL | 3.33 mg/mL | 0.525 mL | 52.5 units |
| 5 mL | 2 mg/mL | 0.875 mL | 87.5 units |
This is why any discussion of pt-141 dosage in ml is meaningless without the concentration. The same 0.35 mL delivers 3.5 mg from a 10 mg/mL vial and 1.75 mg from a 5 mg/mL vial.
Anyone working through pt-141 10mg reconstitution and dosage should write the concentration directly on the vial before drawing a single unit, and should treat U-100 markings as volume, never as milligrams.
PT-141 Dosage for Women vs. Men
The FDA approval covers premenopausal women with HSDD only. That is the population where pt-141 dosage for women has a defined answer: 1.75 mg subcutaneously, as needed, with the 24-hour and eight-dose limits applied.
Men were included in earlier trials of bremelanotide, but results were mixed and the drug was never approved for male use. Studies that enrolled men tested roughly 1.75 mg to 2 mg by injection and about 10 mg by nasal spray.
Most people searching for pt-141 peptide dosage for men are reading trial protocols rather than an approved label, and those numbers should not be treated as interchangeable with the approved female dose.
Postmenopausal women fall outside the approved population as well, so use in that group is off-label and should be supervised by a clinician.
Risks of Using PT-141 More Often Than Directed
- Blood pressure elevation. Bremelanotide raises blood pressure temporarily, and frequent dosing means more time in that window.
- Nausea. Reported in roughly 40% of clinical trial participants and often the reason people stop treatment.
- Focal hyperpigmentation. Dark patches on the skin, gums, or breasts have been reported, and risk appears to rise with cumulative exposure.
- Flushing and headache. Common and usually short-lived, but more noticeable when doses are repeated.
PT-141 is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease.
Bremelanotide is also processed in part by the same liver enzymes as many common medications, so a clinician should review your complete medication list before any dose is used.
Reading a Dosage Chart Safely
A trustworthy pt-141 peptide dosage chart starts from the 1.75 mg labeled dose and the once-per-24-hour limit, not from a daily schedule copied between forums.
Compounded and research-grade bremelanotide products are not FDA-approved, which means potency and purity can vary from one vial to the next. A dose that behaved predictably with one batch may not match the next.
If you are considering bremelanotide, talk with a healthcare professional who can review your blood pressure, medications, and cardiovascular history. Ask whether the approved product or a compounded version is appropriate for you, and never shorten the interval between doses on your own.
Frequently Asked Questions
Can you take PT-141 every day?
No. The Vyleesi label permits a single 1.75 mg subcutaneous dose, no more than once in 24 hours and no more than eight doses per month. No clinical trial has established a safe daily schedule for bremelanotide.
What is the PT-141 dosage for men?
PT-141 is not FDA-approved for men in the United States. Trials that enrolled men studied roughly 1.75 mg to 2 mg by injection and about 10 mg by nasal spray, with mixed results on efficacy.
How do you reconstitute a 10 mg vial of PT-141?
Adding 1 mL of bacteriostatic water to a 10 mg vial creates a 10 mg/mL solution, 2 mL creates 5 mg/mL, and 5 mL creates 2 mg/mL. A 1.75 mg dose equals 0.175 mL, 0.35 mL, or 0.875 mL respectively, so the volume only makes sense alongside the concentration.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.